Single Dose ADME Study of [14C]SJP-0008 in Healthy Male Subjects
- Registration Number
- NCT05320861
- Lead Sponsor
- Senju Pharmaceutical Co., Ltd.
- Brief Summary
This single centre, open-label, non-randomised, single period, single-dose study in healthy male subjects was designed and conducted to assess the mass balance recovery, PK, metabolite profile and metabolite identification of SJP-0008.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 6
Inclusion Criteria
- Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening
- Must be willing and able to communicate and participate in the whole study
- Must have regular bowel movements
- Must provide written informed consent
- Must agree to adhere to the contraception requirements of the protocol
Exclusion Criteria
- Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1
- Subjects who are, or are immediate family members of, a study site or sponsor employee
- Subjects who report to have previously received SJP-0008
- Evidence of current SARS-CoV-2 infection
- History of any drug or alcohol abuse in the past 2 years
- Regular alcohol consumption in males >21 units per week
- A confirmed positive alcohol breath test at screening or admission
- Current smokers and those who have smoked within the last 6 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
- Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 6 months
- Subjects with pregnant or lactating partners
- Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study
Other protocol-defined exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description [14C]SJP-0008 [14C]SJP-0008 -
- Primary Outcome Measures
Name Time Method Mass balance recovery of total radioactivity in all excreta after a single oral dose of [14C]SJP-0008 Until the mass balance criteria for all participants have been met (estimated up to Day 10) Mass balance recovery of total radioactivity in all excreta by analysing the total radioactivity and metabolic profile in plasma, urine and faeces samples.
- Secondary Outcome Measures
Name Time Method Maximum plasma concentration (Cmax) of SJP-0008 and SNJ-2026 Up to Day 8 Area under the concentration-time curve from time zero to last measurable concentration (AUC0-last) of SJP-0008 and SNJ-2026 Up to Day 8 Area under the concentration-time curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUCextrap) of SJP-0008 and SNJ-2026 Up to Day 8 Area under concentration-time curve from time zero to infinity (AUC0-inf) of SJP-0008 and SNJ-2026 Up to Day 8 Time to maximum plasma concentration (Tmax) of SJP-0008 and SNJ-2026 Up to Day 8 Half-life (T1/2) of SJP-0008 and SNJ-2026 Up to Day 8 First order rate constant associated with the terminal (log-linear) portion of the curve (Lambda-z) of SJP-0008 and SNJ-2026 Up to Day 8 Percentage of participants with adverse events (AEs) Until the mass balance criteria for all participants have been met (estimated up to Day 10)
Trial Locations
- Locations (1)
Quotient Sciences
🇬🇧Ruddington, Nottingham, United Kingdom